Cure8 research brief
A simple blood-derived neutrophil activation marker (Neut-RI) correlated with clinical disease activity in ulcerative colitis and outperformed fecal calprotectin and CRP in this study, suggesting a potential low-cost, non-invasive test for monitoring UC.
Clinicians treating UC, researchers studying IBD biomarkers, clinical labs evaluating new hematology markers, and patients interested in non-invasive monitoring options.
This prospective clinical study tested two neutrophil activation markers (Neutrophil Reactivity Intensity, Neut-RI; and Neutrophil Granularity Intensity, Neut-GI) measured on a Sysmex XN-9000 analyzer in blood from 68 patients with a suspected UC flare and 71 healthy controls. Neut-RI and Neut-GI were higher in UC patients than controls.
Neut-RI showed a moderate correlation with Mayo and SCCAI clinical scores and discriminated patients with proctitis from those with more extensive disease. The authors report that Neut-RI outperformed fecal calprotectin and CRP in correlating with clinical activity in this cohort.
The work is presented as a promising, low-cost, non-invasive biomarker for UC disease activity but is reported from a single prospective study and uses a specific hematology platform (Sysmex XN-9000). It may require external validation and comparison with endoscopic endpoints before changing practice.
Findings come from a single prospective study using the Sysmex XN-9000 analyzer and rely on clinical scores rather than reported endoscopic endpoints; external validation is needed.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
